WO2022212845A3 - Pd-1- and ox40l-based chimeric proteins - Google Patents

Pd-1- and ox40l-based chimeric proteins Download PDF

Info

Publication number
WO2022212845A3
WO2022212845A3 PCT/US2022/023054 US2022023054W WO2022212845A3 WO 2022212845 A3 WO2022212845 A3 WO 2022212845A3 US 2022023054 W US2022023054 W US 2022023054W WO 2022212845 A3 WO2022212845 A3 WO 2022212845A3
Authority
WO
WIPO (PCT)
Prior art keywords
ox40l
chimeric proteins
based chimeric
extracellular domain
human
Prior art date
Application number
PCT/US2022/023054
Other languages
French (fr)
Other versions
WO2022212845A2 (en
Inventor
Arundathy PANDITE
Fatima RANGWALA
Thomas LAMPKIN
Taylor Schreiber
George FROMM
Suresh DE SILVA
Original Assignee
Shattuck Labs, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs, Inc. filed Critical Shattuck Labs, Inc.
Publication of WO2022212845A2 publication Critical patent/WO2022212845A2/en
Publication of WO2022212845A3 publication Critical patent/WO2022212845A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present technology relates, inter alia, to methods of treating cancer with chimeric proteins comprising an extracellular domain of human programmed cell death protein 1 (PD-1) and an extracellular domain of human 0X40 Ligand (OX40L), including doses and regimens.
PCT/US2022/023054 2021-04-01 2022-04-01 Pd-1- and ox40l-based chimeric proteins WO2022212845A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163169336P 2021-04-01 2021-04-01
US63/169,336 2021-04-01
US202163229245P 2021-08-04 2021-08-04
US63/229,245 2021-08-04
US202163231581P 2021-08-10 2021-08-10
US63/231,581 2021-08-10
US202163278565P 2021-11-12 2021-11-12
US63/278,565 2021-11-12

Publications (2)

Publication Number Publication Date
WO2022212845A2 WO2022212845A2 (en) 2022-10-06
WO2022212845A3 true WO2022212845A3 (en) 2022-11-10

Family

ID=83460007

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/023054 WO2022212845A2 (en) 2021-04-01 2022-04-01 Pd-1- and ox40l-based chimeric proteins

Country Status (1)

Country Link
WO (1) WO2022212845A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020047325A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020047325A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FROMM ET AL.: "Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy", J IMMUNOTHER CANCER, vol. 6, no. 1, 18 December 2018 (2018-12-18), pages 1 - 16, XP021266120, DOI: 10.1186/s40425-018-0454-3 *

Also Published As

Publication number Publication date
WO2022212845A2 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
CR20220396A (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
RU2016135062A (en) DIRECTED INHIBITION OF TGF BETA
WO2019108733A3 (en) Cd47 antibodies and uses thereof for treating cancer
EA201990230A1 (en) PROTEIN BINDING LIGAND 1 OF PROGRAMMED DEATH 1 (PD-L1), AND METHODS FOR USING THEM
WO2018209194A3 (en) Newcastle disease viruses and uses thereof
EP2196474A3 (en) Therapeutic targets in cancer
NO20064794L (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
EA202091539A1 (en) COMBINED THERAPY AGAINST MALIGNANT TUMOR WITH ANTAGONIST IAP AND MOLECULE AGAINST PD-1
WO2019056023A3 (en) Claudin6 antibodies and methods of treating cancer
Morgunova et al. Interpretation of data about the impact of biologically active compounds on viability of cultured cells of various origin from a gerontological point of view
WO2017100663A8 (en) Improved methods for treating her2-positive breast cancer
WO2004031231A3 (en) Genes and polypeptides relating to prostate cancers
WO2022212845A3 (en) Pd-1- and ox40l-based chimeric proteins
EP4292606A3 (en) Compositions for treating cancer
DE60133104D1 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF NEOPLASTIC DISEASES BY CHEMOTHERAPY AND RADIATION SENSITISTS
Sun et al. A 1.8-GHz radiofrequency radiation induces EGF receptor clustering and phosphorylation in cultured human amniotic (FL) cells
WO2019066620A3 (en) Anti-c-met antibody and uses thereof
MX2022001515A (en) Cetuximab-ir700 conjugate compositions.
MX2023003142A (en) Clinical dosing of sirp1a chimeric protein.
Zhao et al. CD37 is a potential therapeutic target for B-cell non-Hodgkin lymphoma
Krutwa Small-scale differences in tropical subtidal rocky reef communities of Floreana Island, Galápagos
WO2021081457A3 (en) Methods and agents for enhancing t cell therapies
MXPA05009715A (en) Antibody against tumor specific antigen as target.
WO2021092555A3 (en) Methods of screening to determine effective dosing of cancer therapeutics
WO2021003050A3 (en) Cd38-binding agents and uses thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22782294

Country of ref document: EP

Kind code of ref document: A2